Clinical Trial Update: Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating lenalidomide plus gemcitabine as first-line treatment for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Carcinoma Metastatic
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Maria Liljefors | Conditions: Pancreatic Carcinoma Metastatic, Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED